Phase IA study of TNT009 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2016
At a glance
- Drugs BIVV-009 (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Proof of concept
- 15 Jan 2016 New trial record
- 05 Jan 2016 According to True North Therapeutics media release, the company presented the results of this trial validating TNT009's proof-of-mechanism along with the overall development plan for TNT009 at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016.